Neoantigens, which are unique markers that distinguish cancer cells from other cells, offer a new approach to cancer treatment. These markers help strengthen immunity against cancer, aiding in the prevention of disease recurrence. An artificial intelligence-based personalized cancer vaccine design technology developed by researchers at the Korea Advanced Institute of Science and Technology (KAIST) is enabling significant advancements in this field.
Redaksiya reports that the KAIST research team has ensured that cancer vaccines go beyond single attacks and short-term memory by increasing the reactivity of B cells. This means achieving long-term immunity that "remembers" cancer and prevents its recurrence. This technology optimizes anti-cancer effects for each individual.
Neoantigens are unique antigens present only in cancer cells. These antigens act as targets for the immune system to recognize and destroy cancer cells. KAIST researchers are developing personalized vaccines by identifying the most suitable neoantigens for each patient using artificial intelligence. This approach allows for more effective outcomes in cancer treatment.
This new technology not only increases the effectiveness of cancer vaccines but also ensures their safety. Personalized vaccines are designed to be compatible with the patient's immune system, which reduces the risk of side effects. KAIST researchers believe this technology will play a crucial role in cancer treatment in the future. Their goal is to offer more effective and personalized approaches in the fight against cancer. This could mark the beginning of a new era in the treatment of cancer.